Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Psivida Corp Com (PSDV)

Psivida Corp Com (PSDV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Psivida Corp Com 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472 USA

www.psivida.com P: 617-926-5000

Sector:

Medical

INDUSTRY GROUPING:

Medical - Biomedical

Description:

pSivida Corp., a specialty pharmaceutical company, combines existing drugs with its sustained release delivery technologies to develop transformational products primarily in ophthalmology. pSivida's two proprietary technology systems are Durasert and Tethadur. Durasert delivers specific quantities of drugs at controlled rates for predetermined periods of time from weeks to months. pSivida has developed three of the four sustained delivery release devices for retinal diseases that have been approved in either the US or Europe, the most recent being ILUVIEN', partnered with Alimera Sciences and approved in multiple EU countries. Independently, pSivida is developing an injectable, bioerodible product to treat glaucoma and ocular hypertension. Tethadur is a protein, peptide and antibody delivery system.

Key Statistics

Overview:

Market Capitalization, $K 55,217
Shares Outstanding, K 45,260
% of Insider Shareholders 3.49%
% of Institutional Shareholders 10.69%

Financials:

Annual Sales, $ 7,540 K
Annual Net Income, $ -18,490 K
Last Quarter Sales, $ 930 K
Last Quarter Net Income, $ -5,780 K

Growth:

1-Year Return -32.22%
3-Year Return -68.31%
5-Year Return -46.02%
5-Year Revenue Growth 113.31%
5-Year Earnings Growth 8.33%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 05/03/18
Earnings Per Share ttm -0.59
EPS Growth vs. Prev Qtr 13.33%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-4 on 06/26/08

PSDV Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -205.82%
Return-on-Assets % -144.60%
Profit Margin % -245.23%
Debt/Equity 0.00
Price/Sales 6.42
Price/Cash Flow N/A
Price/Book 5.58
Book Value/Share 0.22
Interest Coverage 0.00
60-Month Beta 1.28
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.